Findings help identify patients who may not be optimally managed for recurrent stroke prevention
News | Stroke
Continuous Monitoring Detects Four Times More Atrial Fibrillation Incidence Following Stroke than Intermittent Monitoring

May 18, 2022 — Continuous monitoring with an insertable cardiac monitor (ICM) is shown to be more successful in ...

Home May 18, 2022
Home
Khaldoon Alaswad, M.D., director of catheterization lab at Henry Ford Hospital in Detroit. Image courtesy of Henry Ford Health
News | Chronic Total Occlusion (CTO)
Henry Ford Cardiologist to Perform a Live Heart Procedure at International Medical Education Event

May 18, 2022 — For the third straight year, Henry Ford Hospital interventional cardiologist Khaldoon Alaswad, M.D. will ...

Home May 18, 2022
Home
Results indicate Black patients are 25% less likely to receive stroke-preventing medication
News | Atrial Fibrillation
Study of National Registry Uncovers Racial Disparities Around Anticoagulation for Atrial Fibrillation

May 17, 2022 — Results of a new study reveal Black patients hospitalized with atrial fibrillation (AF) are under ...

Home May 17, 2022
Home
Innovative care strategy created in response to COVID-19 pandemic emphasizes the role telemedicine plays in post-op patient monitoring
News | Atrial Fibrillation
New Study Shows Benefits of Same Day Discharge for Atrial Fibrillation Ablation Patients

May 17, 2022 — Results from a new study show success of intended same day discharge (SDD) improves over time for ...

Home May 17, 2022
Home
Heart Rhythm 2022 has come to a close, and the Heart Rhythm Society has released some stats regarding this year's conference. More than 7,700+ heart rhythm professionals from around the world whose participation during Heart Rhythm 2022
News | HRS
Heart Rhythm 2022 Highlights

May 17, 2022 — Heart Rhythm 2022 has come to a close, and the Heart Rhythm Society has released some stats regarding ...

Home May 17, 2022
Home
Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs
News | Pharmaceuticals
Research Shows Potential to Reduce Major Cardiovascular (CV) Events

May 17, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 17, 2022
Home
On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, Inc. announced that it has expanded the company’s focus beyond structural heart disease into cardiovascular (CV) disease, starting with atrial fibrillation (AF).
News | Atrial Fibrillation
egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation

May 17, 2022 — On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the ...

Home May 17, 2022
Home
Seamless integration and communication between Philips Ultrasound System - EPIQ CVxi - and Philips Image Guided Therapy System - Azurion - supports efficient fusion-imaging workflow for minimally-invasive treatment of structural heart disease
News | Structural Heart
Philips EchoNavigator Helps Interventional Teams Treat Structural Heart Disease

May 16, 2022 — Philips, a global leader in health technology, announced at EuroPCR (17 - 20 May 2022, Paris, France) the ...

Home May 16, 2022
Home
Boston Scientific announced that Peter M. “Pete” Nicholas, co-founder and former CEO of Boston Scientific from 1979 to 1999 and a corporate visionary in the minimally invasive surgery industry, passed away peacefully on May 14 just a few days before his 81st birthday. 
News | Cardiovascular Business
Boston Scientific Co-founder and Former CEO Passes Away

May 16, 2022 — Boston Scientific announced that Peter M. “Pete” Nicholas, co-founder and former CEO of Boston Scientific ...

Home May 16, 2022
Home
Key members of the research collaboration: (from left) Prof Roger Foo (Programme Director, ATTRaCT, and Senior Group Leader, GIS), Dr Karin Conde-Knape (Senior Vice President, Global Drug Discovery, Novo Nordisk), Dr Rasmus Rabøl (Corporate Vice President, Global Translation, Novo Nordisk), Dr Natasha Michaelsen (Principal Scientist, Global Translation, Novo Nordisk), Prof Mark Richards (Director, Cardiovascular Research Institute, NUS, and Deputy Director, National University Heart Centre), Prof Derek Haus
News | Heart Failure
A*STAR, NHCS, NUS, and Novo Nordisk to Collaborate on Cardiovascular Disease Research

May 16, 2022 — The Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS) and ...

Home May 16, 2022
Home
A substantial proportion of patients with COVID and shock had low CI despite preserved EF, suggesting underfilling of the LV, but this proportion was smaller in W2. This difference could not be explained by changes in PEEP between cohorts. This suggests that fluid management strategies may have been more aggressive in W2.
News | Coronavirus (COVID-19)
New Report Published Comparing Hemodynamics of Cardiac Shock in COVID-19 Patients in Pandemic’s First Vs. Second Wave

May 16, 2022 — A new report by a team of cardiologists from the Heart & Vascular Hospital, Hackensack Meridian ...

Home May 16, 2022
Home
Pump housing and impeller design. (A): (left) Axial flow pump: HeartMate II LVAD (taken from Figure 2 in the HeartMate II left ventricular assist system instructions for use). (B) (right) Centrifugal flow pump: HeartWare assist device (taken from Figure 2 in the HeartWare assist device patient manual).
News | Heart Failure
Study Finds that Concurrent Tricuspid Valve Surgery and Left Ventricular Assist Device Implantation do not Appear to Lower the Incidence of Right Heart Failure

May 16, 2022 — Right heart failure (RHF) continues to be a major source of morbidity and mortality following left ...

Home May 16, 2022
Home
CRF Meeting Covering Structural Heart Disease Innovations Will Take Place June 8-10
News | TVT
Late-Breaking Science Announced for TVT 2022

May 16, 2022 — The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature ...

Home May 16, 2022
Home
Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData
News | Pharmaceuticals
Bristol Myers Squibb’s Mavacamten Poised to Stand unchallenged

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...

Home May 13, 2022
Home
Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced successful completion of patient enrollment in the company’s AcQForce Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally
News
Acutus Medical Completes Enrollment in IDE Trial with its AcQBlate FORCE Sensing Ablation System

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now